Leaf Expression Systems launches first line of Hypertrans research products
Plant-expression deal for difficult to produce proteins, vaccines, metabolites and natural proteins.
Leaf Expression Systems, a contract development and manufacturing organisation specialising in the plant-based expression and production of proteins, vaccines, metabolites and complex natural proteins, has launched its online list of products available for purchase by researchers working within the life sciences and agricultural industries.
The products are produced in Nicotiana benthamiana using Hypertrans, Leaf’s Agrobacterium-mediated transient expression technology. Hypertrans is efficient, safe and simple to use to quickly produce proteins, vaccines, antibodies or enzymes in plants.
The products; Bet v 1-A - Betula verrucosa (European white birch) allergen 1-A, Cowpea Mosaic Virus VLPs, Horseradish Peroxidase (HRP) C1A, Human Nucleotide triphosphate diphosphatase NUDT15 (MTH2), MAb Anti-VEGF 165A, Phleum pratense (Common timothy) allergen 1 and Triosephosphate Isomerase (TPI) are all available for purchase for research purposes via its online platform.
Simon Saxby, CEO said: "We are excited to launch our first proprietary products produced in plants using Hypertrans. We will continue to add products that are difficult or uneconomical to produce using other expression systems to add to the research tools available to the life science community and which also demonstrate the extreme flexibility and capability of Hypertrans for the rapid manufacture of a wide range of biologics on commercially viable scales."
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.